Clinical TopicsGlobal BulletinAll NewsApproval Alert
2 Minute DrillAround the PracticeBetween the LinesBreaking BarriersFace OffFrom All AnglesMeeting of the MindsMorning RoundsOncViewPodcastsReadout 360Sponsored MediaTraining AcademyTreatment Algorithms with the Oncology Brothers
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Contemporary ConceptsAwareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsored
Career CenterSubscribe
Adverse Effects
Biomarkers
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Hormone-related Cancers
Immunotherapy
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
LymphomaLymphoma
Melanoma
Mesothelioma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Around the Practice
  • Between the Lines
  • Contemporary Concepts
  • Journal
  • OncView
  • Podcasts
  • Readout 360
  • Insights from Experts at Mayo Clinic on Translating Evidence to Clinical Practice
  • Optimizing Outcomes in Patients with HER2+ Metastatic Breast Cancer
Adverse Effects
Biomarkers
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Hormone-related Cancers
Immunotherapy
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
LymphomaLymphoma
Melanoma
Mesothelioma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Burnout: Which Way Out?

April 25, 2023
By Julie M. Vose, MD, MBA
Publication
Article
OncologyONCOLOGY Vol 37, Issue 4
Volume 37
Issue 4
Pages: 161

Co-editor-in-Chief Julie M. Vose, MD, MBA, writes about the effects and prevalence of burnout amongst oncologists and reviews strategies to address the issue.

Burnout and the related morale injury it causes are characterized by physical and/or emotional exhaustion, depersonalization, and decreased effectiveness. Burnout is all too common in physicians and is estimated to affect at least 50% of physicians at some point in their career.1 Many systemic risk factors contribute to this epidemic, including high patient volumes, increased administrative burden, lack of “user-friendly” electronic medical records, and lack of organizational infrastructure. Personal risk factors include being female, not having a spouse or partner, and being of younger age.

Oncologists are particularly at risk for burnout due to the difficult patient population we treat, continuous exposure to life-threatening illnesses, and psychological distress.

By now we can all identify burnout and stress. The more important question is what to do about it. Physician wellness starts with us: getting the rest we need, eating a healthy diet, exercising, doing activities that are not work related, and identifying and reducing unnecessary stress. The harder part is, how can we get the health care system to recognize stress in physicians and work with us on modifications to decrease the stress and burnout?

There is only so much any 1 physician can do on their own to reduce stress without infrastructure modifications. Research comparing the effectiveness of individual vs organizational interventions suggests that institutional interventions are much more effective than individual approaches alone, but both approaches when used together are the most effective in reducing burnout.2

How can health care professionals improve the systemic infrastructure that contributes to burnout? We need to work with the health care organization to build system-level interventions aimed at reducing environmental stressors and improve the workplace infrastructure support. One example of a program with such a design is the University of Colorado APEX (Awesome Patient Experience) teamwork model, which incorporates medical assistants to decrease administrative burdens on providers. After this system was implemented, the physician burnout rate was reduced from 53% to 13%.3

In addition, a thorough evaluation of the necessity of all online learning modules and excess meetings and committees and a reevaluation of patient volumes per provider are needed to move toward the future. Another example of an available program to help institutions is the American Medical Association STEPS Forward.4 This program recommends 9 strategies—engagement of leadership, acknowledgment and routine of longitudinal burnout assessments, creation of infrastructure for implementation of individual and system-level interventions, workflow efficiency, reduction in administrative burdens, support for the health of the workforce, strengthening of local leadership, tracking organizational costs of burnout, and routine assessment of interventions—to promote organizational health and employee well-being.

The most important aspect of improving burnout is for physicians to work with the administrative and health care teams and to advocate for themselves. Medicine is a team sport, and all the players need to work together for the same goal.

REFERENCES

  1. Shanafelt TD, West CP, Sinsky C, et al. Changes in burnout and satisfaction with work-life integration in physicians and the general US working population between 2011 and 2017. Mayo Clin Proc. 2019;94(9):1681-1694. doi:10.1016/j. mayocp.2018.10.023
  2. Panagioti M, Panagopoulou E, Bower P, et al. Controlled interventions to reduce burnout in physicians: a systematic review and meta-analysis. JAMA Intern Med. 2017;177(2):195-205. doi:10.1001/ jamainternmed.2016.7674
  3. Wright AA, Katz IT. Beyond burnout - redesigning care to restore meaning and sanity for physicians. N Engl J Med. 2018;378(4):309-311. doi:10.1056/ NEJMp1716845
  4. Redesign your practice: reignite your purpose. AMA Ed Hub. STEPS Forward. Accessed March 17, 2023. https://bit.ly/3YQq4z2
Download Issue PDFDownload PDF
Articles in this issue

Emerging Strategies to Manage Relapsed and/or Refractory Multiple Myeloma
Emerging Strategies to Manage Relapsed and/or Refractory Multiple Myeloma
Advancement Continues in ‘Go-to’ Strategies for Gynecologic Cancer
Advancement Continues in ‘Go-to’ Strategies for Gynecologic Cancer
Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal Adenocarcinoma
Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal Adenocarcinoma
The Management of Relapsed and Refractory Multiple Myeloma
The Management of Relapsed and Refractory Multiple Myeloma
Burnout: Which Way Out?
Burnout: Which Way Out?
Recent Videos
Related Content
Advertisement

96 Elacestrant Real-World Progression-Free Survival of Adult Patients With ER+/HER2–, Advanced Breast Cancer: A Retrospective Analysis Using Insurance Claims in the United States

96 Elacestrant Real-World Progression-Free Survival of Adult Patients With ER+/HER2–, Advanced Breast Cancer: A Retrospective Analysis Using Insurance Claims in the United States

Elyse Swallow;Jessica Maitland;Kirthana Sarathy;Ellen Sears;Yasir Nagarwala;Janelle DePalantino;Eric Kruep;Corey Pelletier;Sebastian Kloss;Tomer Wasserman
April 18th 2025
Article

Stem Cell Transplant Approaches for Patients With Blood Cancers

Stem Cell Transplant Approaches for Patients With Blood Cancers

David T. Scadden, MD
March 13th 2019
Podcast

Dr. Scadden discusses which blood cancer patients are eligible for stem cell transplantation, as well as the latest advances in the field.


97 Treatment Discontinuation Among Patients With Stage IV HER2–Negative Breast Cancer

97 Treatment Discontinuation Among Patients With Stage IV HER2–Negative Breast Cancer

Chia Jie Tan;Connor Willis;Trang Au;Matthew Schabath, PhD;Chenghui Li;Kristen Kelley;Xiaoqing Xu;Leah Park;Clara Lam;Sandhya Mehta;Jackie Kwong;Diana Brixner;David Stenehjem
April 17th 2025
Article

Current Treatment of Esophageal Cancer and Promising Clinical Trials Underway

Current Treatment of Esophageal Cancer and Promising Clinical Trials Underway

Geoffrey Y. Ku, MD
March 13th 2019
Podcast

Dr. Ku discusses considerations in the treatment of esophageal cancer, current treatments, and the emerging role of immunotherapy.


TPS 99 Phase 3, Randomized, Open-Label TroFuse-010 Study of Sacituzumab Tirumotecan Alone and With Pembrolizumab Versus Treatment of Physician’s Choice Chemotherapy in Patients With HR+/HER2– Unresectable Locally Advanced or Metastatic Breast Cancer

TPS 99 Phase 3, Randomized, Open-Label TroFuse-010 Study of Sacituzumab Tirumotecan Alone and With Pembrolizumab Versus Treatment of Physician’s Choice Chemotherapy in Patients With HR+/HER2– Unresectable Locally Advanced or Metastatic Breast Cancer

Sara M. Tolaney, MD, MPH;Paolo D’Amico;Liyi Jia;Kim M. Hirshfield;Fatima Cardoso
April 16th 2025
Article

Advancing Biomedical Research on Salivary Antioxidants: Exploring the Significance in Oral Precancer and Cancer

Advancing Biomedical Research on Salivary Antioxidants: Exploring the Significance in Oral Precancer and Cancer

Vidya G Doddawad, BDS, MDS;B.M. Gurupadayya;Vidya CS;Shivananda S, BDS, MDS;Karthikeya Patil;R. Sumukh Bharadwaj
April 16th 2025
Article

Human saliva may hold antioxidants that are able to monitor the oral cavity's oxidative processes and offer guidance for the development of new drugs.

Related Content
Advertisement

96 Elacestrant Real-World Progression-Free Survival of Adult Patients With ER+/HER2–, Advanced Breast Cancer: A Retrospective Analysis Using Insurance Claims in the United States

96 Elacestrant Real-World Progression-Free Survival of Adult Patients With ER+/HER2–, Advanced Breast Cancer: A Retrospective Analysis Using Insurance Claims in the United States

Elyse Swallow;Jessica Maitland;Kirthana Sarathy;Ellen Sears;Yasir Nagarwala;Janelle DePalantino;Eric Kruep;Corey Pelletier;Sebastian Kloss;Tomer Wasserman
April 18th 2025
Article

Stem Cell Transplant Approaches for Patients With Blood Cancers

Stem Cell Transplant Approaches for Patients With Blood Cancers

David T. Scadden, MD
March 13th 2019
Podcast

Dr. Scadden discusses which blood cancer patients are eligible for stem cell transplantation, as well as the latest advances in the field.


97 Treatment Discontinuation Among Patients With Stage IV HER2–Negative Breast Cancer

97 Treatment Discontinuation Among Patients With Stage IV HER2–Negative Breast Cancer

Chia Jie Tan;Connor Willis;Trang Au;Matthew Schabath, PhD;Chenghui Li;Kristen Kelley;Xiaoqing Xu;Leah Park;Clara Lam;Sandhya Mehta;Jackie Kwong;Diana Brixner;David Stenehjem
April 17th 2025
Article

Current Treatment of Esophageal Cancer and Promising Clinical Trials Underway

Current Treatment of Esophageal Cancer and Promising Clinical Trials Underway

Geoffrey Y. Ku, MD
March 13th 2019
Podcast

Dr. Ku discusses considerations in the treatment of esophageal cancer, current treatments, and the emerging role of immunotherapy.


TPS 99 Phase 3, Randomized, Open-Label TroFuse-010 Study of Sacituzumab Tirumotecan Alone and With Pembrolizumab Versus Treatment of Physician’s Choice Chemotherapy in Patients With HR+/HER2– Unresectable Locally Advanced or Metastatic Breast Cancer

TPS 99 Phase 3, Randomized, Open-Label TroFuse-010 Study of Sacituzumab Tirumotecan Alone and With Pembrolizumab Versus Treatment of Physician’s Choice Chemotherapy in Patients With HR+/HER2– Unresectable Locally Advanced or Metastatic Breast Cancer

Sara M. Tolaney, MD, MPH;Paolo D’Amico;Liyi Jia;Kim M. Hirshfield;Fatima Cardoso
April 16th 2025
Article

Advancing Biomedical Research on Salivary Antioxidants: Exploring the Significance in Oral Precancer and Cancer

Advancing Biomedical Research on Salivary Antioxidants: Exploring the Significance in Oral Precancer and Cancer

Vidya G Doddawad, BDS, MDS;B.M. Gurupadayya;Vidya CS;Shivananda S, BDS, MDS;Karthikeya Patil;R. Sumukh Bharadwaj
April 16th 2025
Article

Human saliva may hold antioxidants that are able to monitor the oral cavity's oxidative processes and offer guidance for the development of new drugs.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.